Justia Antitrust & Trade Regulation Opinion Summaries

Fred Duran filed a putative class action complaint against Obesity Research Institute, LLC (ORI) and Wal-Mart Stores, Inc. (Wal-Mart) (collectively, defendants). Duran alleged defendants falsely claimed that ORI's products, Lipozene and MetaboUp, had weight loss benefits. The court approved a claims-made settlement providing that class members submitting a claim without proof of purchase would receive $15, and those submitting receipt(s) would receive one refund of double the unit price paid. The settlement also provided that ORI would cease making certain assertions in product advertising. Defendants also agreed to not oppose a motion seeking $100,000 in attorney fees to class counsel. Objectors, class members DeMarie Fernandez, Alfonso Mendoza, and Brian Horowitz appealed, contending the settlement was the product of collusion. Objectors claimed the class did not receive sufficient notice of settlement, and the settlement was unreasonable and inadequate. They also contended the attorney fee award was excessive. The Court of Appeal reviewed the case and concluded that the trial court's judgment had to be reversed because the class notice failed in its fundamental purpose, to apprise class members of the terms of the proposed settlement. "The erroneous notice injected a fatal flaw into the entire settlement process and undermines the court's analysis of the settlement's fairness." View "Duran v. Obesity Research Institute" on Justia Law

In an antitrust class action brought on behalf of approximately 12 million merchants against Visa and Mastercard, as well as other various banks, plaintiffs alleged conspiracy in violation of Section 1 of the Sherman Act, 15 U.S.C. 1. After the parties agreed to a settlement releasing all claims, the district court certified two settlement-only classes and approved the settlement. Numerous objectors and opt‐out plaintiffs appealed and argued that the class action was improperly certified and that the settlement was unreasonable and inadequate. The court concluded that class members of the (b)(2) class were inadequately represented in violation of both FRCP 23(a)(4) and the Due Process Clause. The court also concluded that procedural deficiencies produced substantive shortcomings in this class action and the settlement. Consequently, the court concluded that the class action was improperly certified and the settlement was unreasonable and inadequate. The court vacated the district court's certification of the class action and reversed the approval of the settlement. The court remanded for further proceedings. View "In re Payment Card Interchange Fee and Merchant Discount Antitrust" on Justia Law

Blue Cross controls more than 60% of the Michigan commercial health insurance market; its patients are more profitable for hospitals than are patients insured by Medicare or Medicaid. BC enjoys “extraordinary market power.” The Justice Department (DOJ) claimed that BC used that power to require MFN agreements: BC would raise its reimbursement rates for services, if a hospital agreed to charge other commercial insurers rates at least as high as charged to BC. BC obtained MFN agreements with 40 hospitals and MFN-plus agreements with 22 hospital systems. Under MFN-plus, the greater the spread between BC's rates and the minimum rates for other insurers, the higher the rates that BC would pay. Class actions, (consolidated) followed the government’s complaint, alleging damages of more than $13.7 billion, and seeking treble damages under the Sherman Act, 15 U.S.C 15. In 2013, Michigan banned MFN clauses; DOJ dismissed its suit. During discovery in the private actions, plaintiffs hired an antitrust expert, Leitzinger. BC moved to exclude Leitzinger’s report and testimony. Materials relating to that motion and to class certification were filed under seal, although the report does not discuss patient information. BC agreed to pay $30 million, about one-quarter of Leitzinger's estimate, into a settlement fund and not to oppose requests for fees, costs, and named-plaintiff “incentive awards,” within specified limits. After these deductions, $14,661,560 would be allocated among three-to-seven-million class members. Class members who sought to examine the court record or the bases for the settlement found that most key documents were heavily redacted or sealed. The court approved the settlement and denied the objecting class members’ motion to intervene. The Seventh Circuit vacated, stating that the court compounded its error in sealing the documents when it approved the settlement without meaningful scrutiny of its fairness to unnamed class members . View "Shane Group, Inc. v. Blue Cross Blue Shield of Mich." on Justia Law

A class action complaint alleged that Honeywell engaged in uncompetitive and illegal conduct to increase its market share of round thermostats and to use its dominant market position to overcharge customers. In 2013, the parties reached a settlement and asked the trial court to preliminarily approve it. The court initially declined to do so because it had concerns about the notice proposed to be sent to class members. Those concerns were subsequently addressed to the court’s satisfaction, and on February 4, 2014, the court preliminarily approved the settlement. The notice of settlement was subsequently published and distributed to class members. The long version was distributed and posted on a website, and the short version was published in various print publications. The trial court found that four objectors to the settlement failed to establish they had standing, but rejected one objection on timeliness grounds and rejected the other three on their merits. The court of appeal affirmed, except for the ruling on standing, finding that the court properly approved the distribution of residual settlement funds and awarded class counsel attorney fees that amounted to 37.5 percent of the settlement fund. View "Roos v. Honeywell Int'l, Inc." on Justia Law

The U.S. chocolate market is dominated by three companies: Hershey, Mars, and Nestlé USA (the Chocolate Manufacturers). A certified class of direct purchasers of chocolate products and a group of individual plaintiffs alleged that the Chocolate Manufacturers conspired to raise prices on chocolate candy products in the United States three times between 2002 and 2007. They offered evidence of a contemporaneous antitrust conspiracy in Canada. The district court granted the defendants summary judgment. The Third Circuit affirmed, finding that the Canadian conspiracy evidence was ambiguous and did not support an inference of a U.S. conspiracy because the people involved in and the circumstances surrounding the Canadian conspiracy are different from those involved in and surrounding the purported U.S. conspiracy; evidence that the U.S. Chocolate Manufacturers knew of the unlawful Canadian conspiracy was weak and, in any event, related only to Hershey. Other traditional conspiracy evidence was insufficient to create a reasonable inference of a U.S. price-fixing conspiracy. View "In re: Chocolate Confectionary Antitrust Litig." on Justia Law

A class action filed against Dairy Farmers of America (DFA), a dairy marketing cooperative, Keller’s Creamery, a butter manufacturer, two DFA officers, and two Keller’s officers, alleged a conspiracy to purchase cheese traded on the Chicago Mercantile Exchange in order to help DFA and Keller’s manipulate the price of Class III milk futures. The parties named in the initial complaint reached a settlement (DFA Settlement), which the district court approved in 2014. In 2012, plaintiffs filed an amended class action complaint, adding Schreiber Foods as a defendant and alleging violations of sections 1 and 2 of the Sherman Act, the California Cartwright Act, the Commodity Exchange Act, and RICO. The district court dismissed the section 2 Sherman Act claims. In 2013, the court granted Schreiber summary judgment on the remaining claims. The Seventh Circuit affirmed, rejecting arguments that the district court abused its discretion by limiting discovery to only “high-level” employees and prohibiting the depositions of several employees and in including Schreiber in the DFA Settlement. View "Indriolo Distribs., Inc. v. Schreiber Food, Inc." on Justia Law

Bayer AG and Bayer Corporation (collectively, Bayer) marketed Cipro, an antibiotic. In 1987, Bayer was issued a United States patent on the active ingredient in Cipro. Twelve years before the expiration of the patent, Barr Laboratories, Inc. filed an application to market a generic version of Cipro. Bayer responded with a patent infringement suit, and Barr counterclaimed for a declaratory judgment that the patent was invalid. In 1997, Bayer and Barr entered into a settlement agreement under which Bayer agreed to make a “reverse payment” to Barr in exchange for Barr dropping its patent challenge and consenting to stay out of the market. The settlement produced numerous state and federal antitrust suits. This case arose from nine such coordinated class action suits brought by indirect purchasers of Cipro in California. The complaint alleged that the Bayer-Barr reverse payment settlement violated the Cartwright Act, unfair competition law, an common law prohibition against monopolies. The trial court granted summary judgment for Bayer and Barr. The Court of Appeal affirmed. The Supreme Court reversed, holding that parties illegally restrain trade when they privately agree to substitute consensual monopoly in place of potential competition that would have followed a finding of invalidity or noninfringement. View "In re Cipro Cases I & II" on Justia Law

Plaintiffs are direct purchasers of traditional blood reagents, used to test blood compatibility between donors and recipients, from Immucor and OrthoClinical (defendants). By 1999, the entire domestic supply of that product was under defendants’ control. In 2000, defendants’ executives attended a trade meeting at which plaintiffs assert the conspiracy began. Defendants soon began rapidly increasing prices. By 2009, many prices had risen more than 2000%. Following a Department of Justice probe, private suits were filed, transferred by the Judicial Panel on Multidistrict Litigation, and consolidated. Plaintiffs sought damages under the Clayton Act, 15 U.S.C. 15, for alleged horizontal price fixing in violation of the Sherman Act, 15 U.S.C. 1. After preliminary approval of plaintiffs’ settlement with Immucor, the court certified plaintiffs’ class of “[a]ll individuals and entities who purchased traditional blood reagents in the United States directly from Defendants ... at any time from January 1, 2000 through the present.” Plaintiffs relied in part on expert testimony to produce their antitrust impact analyses and damages models, which Ortho challenged. The Supreme Court subsequently decided Comcast v. Behrend, which reversed Behrend v. Comcast, on which the district court relied in granting class certification. The Third Circuit vacated, reasoning that the court had no opportunity to consider the implications of Comcast; a court must resolve any Daubert challenges to expert testimony offered to demonstrate conformity with Rule 23 View "In re: Blood Reagents Antitrust Litig." on Justia Law

A class of Netflix DVD subscribers filed a consolidated amended class action against Netflix and Walmart, claiming that a promotion agreement whereby Walmart transferred its online DVD-rental subscribers to Netflix and Netflix agreed to promote Walmart’s DVD sales business was anti-competitive. The district court approved of a settlement between Walmart and the class of Netflix subscribers whereby Walmart agreed to pay a total amount of $27,250,000. The Ninth Circuit affirmed, holding that the district court did not err in (1) approving the settlement as fair, reasonable, and adequate; (2) certifying the settlement class; and (3) awarding attorneys’ fees of twenty-five percent of the overall settlement fund. View "Frank v. Netflix, Inc." on Justia Law

Plaintiffs, individuals representing a class of Netflix subscribers, contended that a promotion agreement whereby Walmart transferred its online DVD-rental subscribers to Netflix and Netflix agreed to promote Walmart’s DVD sales business violated the Sherman Act by illegally allocating and monopolizing the online DVD rental market. The district court granted summary judgment for Netflix and awarded Netflix $710,194 in costs. The Ninth Circuit (1) affirmed the district court’s summary judgment, holding that Plaintiffs did not raise a triable issue of fact as to whether they suffered antitrust in-jury-in-fact on a theory that they paid supracompetitive prices for their DVD-rental subscriptions because Netflix would have reduced its subscription price but for its allegedly anticompetitive product; and (2) affirmed in part and reversed in part the award of costs, holding that certain charges for “data upload” and “keywording” were not recoverable as costs for making copies under 28 U.S.C. 1920(4). Remanded for consideration of whether costs were properly awarded for “professional services.” View "Resnick v. Netflix, Inc." on Justia Law